
Houston Myeloma Roundtable
Join us for the Houston Myeloma Roundtable on October 24th to hear directly from leading myeloma experts about the latest in treatment and research. Designed specifically for patients and caregivers, the event includes patient-friendly presentations, breakout sessions for newly diagnosed and relapsed/refractory patients, and a dedicated faculty Q&A with plenty of time to ask questions.
Meeting Details
Registration & breakfast 8:00 am
Program: 9:00 am - 2:30 pm
Location: TMC3 Collaborative Building, Helix Hall
Breakout sessions & meals: Levy Conference Center
Included: Breakfast, lunch, refreshments, and parking
Nearest airport: George Bush Intercontinental Airport (IAH)
Unable to attend in person? Register to receive access to the event recording.
This event will not be livestreamed. The recording will be available approximately one week after the event, and registered individuals will receive an email when it is ready.
Make it a weekend
If you are traveling to the meeting and would like to make a weekend of it while you are in Houston, here are some suggestions:
Hotels close to the event: Blossom Hotel Houston (special rate link coming soon) and Hyatt Place Houston Medical Center
Restaurants: Terrace 54, Le Petit Chef, and Potbelly
Things to do: Space Center Houston, The Museum of Fine Arts, and Hermann Park
Questions?
For registration questions, contact us at +1 800 709 1113 or email us at support@healthtree.org
To ensure we can continue providing you with excellent venues, quality meals, and a valuable experience at our Roundtable meetings, we're introducing a modest registration fee. If the fee is a financial burden, please contact us for a promotional code to waive the cost.

- Understanding today's standard treatments for newly diagnosed myeloma, including the role of stem cell transplant.
- How immunotherapies and emerging treatments are shaping earlier lines of care
- How bispecific and trispecific antibodies work and where they fit into myeloma treatment today.
- Using antibody-drug conjugates in myeloma care.
- Who may be eligible for CAR T-cell therapy, and when it may be considered
- What patients can expect before, during, and after treatment.
Newly Diagnosed - Living Well Through Treatment: Managing Side Effects and Supportive Care, Michelly De Castro, DNP, AOCNP
OR
Relapsed Refractory - Defining "Cure" in Myeloma: What Does It Mean Today?, Meera Mohan, MD
- How MRD, genetics, and individual patient factors help guide personalized treatment decisions.
- Using today’s expanding myeloma toolbox to build the right treatment strategy over time.
William Matsui, MD
Meera Mohan,MD
Krina Patel, MD
Michelly De Castro, DNP, AOCNP
Sarvari V. Yellapragada, MD

Jenny Ahlstrom

Krina Patel, MD, MSc

Meera Mohan, MD, MS, FACP

William Matsui, MD

Sarvari Yellapragada, MD
Michelly De Castro, DNP, APRN, AGNP-C